April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Apr 24, 2024, 09:58

KEYNOTE-A18 summarised by Sergio Cifuentes

Sergio Cifuentes, Cancer Research Project Manager at 

KEYNOTE-A18.

  • Pembrolizumab + CRT in LACC
  •  mPFS NR in pembrolizumab group

24m PFS: 68% vs 57%

  • Pembrolizumab + CRT led to a 30% reduction in DR
  • OS at 24m: 87% vs 81%

Grade 3 or higher AE: 75% vs 69%.”

Read further.
Source: Sergio Cifuentes/X